These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9233630

  • 1. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
    Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Furukawa K, Kanematsu T, Shiku H.
    J Immunol; 1997 Aug 01; 159(3):1336-43. PubMed ID: 9233630
    [Abstract] [Full Text] [Related]

  • 2. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
    Kuhröber A, Schirmbeck R, Reimann J.
    Eur J Immunol; 1994 May 01; 24(5):1172-80. PubMed ID: 7514132
    [Abstract] [Full Text] [Related]

  • 3. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA, Schlom J, Abrams SI.
    J Immunol; 1998 Mar 01; 160(5):2433-41. PubMed ID: 9498787
    [Abstract] [Full Text] [Related]

  • 4. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN.
    Cancer Res; 2006 May 15; 66(10):5452-60. PubMed ID: 16707474
    [Abstract] [Full Text] [Related]

  • 5. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M, Orosz CG, Bach FH.
    J Immunol; 1984 Jun 15; 132(6):3218-25. PubMed ID: 6202778
    [Abstract] [Full Text] [Related]

  • 6. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
    Gu XG, Schmitt M, Hiasa A, Nagata Y, Ikeda H, Sasaki Y, Akiyoshi K, Sunamoto J, Nakamura H, Kuribayashi K, Shiku H.
    Cancer Res; 1998 Aug 01; 58(15):3385-90. PubMed ID: 9699670
    [Abstract] [Full Text] [Related]

  • 7. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M, Wada H, Honda S, Tawara I, Uenaka A, Kanematsu T, Nakayama E.
    J Immunol; 1999 Jun 01; 162(11):6420-5. PubMed ID: 10352255
    [Abstract] [Full Text] [Related]

  • 8. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.
    Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL.
    Lab Anim Sci; 1999 Apr 01; 49(2):179-88. PubMed ID: 10331548
    [Abstract] [Full Text] [Related]

  • 9. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K.
    Cancer Res; 1993 Jan 01; 53(1):106-11. PubMed ID: 8093229
    [Abstract] [Full Text] [Related]

  • 10. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.
    Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA.
    Hum Immunol; 1997 Feb 01; 52(2):109-18. PubMed ID: 9077559
    [Abstract] [Full Text] [Related]

  • 11. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
    Franke ED, Corradin G, Hoffman SL.
    J Immunol; 1997 Oct 01; 159(7):3424-33. PubMed ID: 9317141
    [Abstract] [Full Text] [Related]

  • 12. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W.
    Cancer Res; 1998 Feb 15; 58(4):732-6. PubMed ID: 9485028
    [Abstract] [Full Text] [Related]

  • 13. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, Gallo P, Amici A, Monaci P, Mattei M, Modesti M, Forni G, Kraus MH, Muraro R, Modesti A, Bei R.
    Int J Oncol; 2007 Feb 15; 30(2):381-92. PubMed ID: 17203220
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
    Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ.
    J Immunol; 1996 May 15; 156(10):3911-8. PubMed ID: 8621930
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ, Stewart TJ, Tindle RW, Frazer IH.
    J Immunol; 1998 Sep 01; 161(5):2421-7. PubMed ID: 9725239
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A glycopeptide extract can inhibit cytotoxic T lymphocyte-target cell conjugation in an H-2-restricted manner.
    Pimlott NJ, Miller RG.
    J Immunol; 1984 Oct 01; 133(4):1763-8. PubMed ID: 6236257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.